Detalhe da pesquisa
1.
Relapses are common in severe hematologic systemic lupus erythematosus and may be prevented by early institution of immunosuppressive agents: Α real-life single-center study.
Lupus
; 32(2): 225-230, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36490217
2.
Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.
Clin Exp Rheumatol
; 41(9): 1831-1837, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37497730
3.
JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus.
Mediterr J Rheumatol
; 35(Suppl 1): 37-44, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38756931
4.
Non-Invasive Assessment of Micro- and Macrovascular Function after Initiation of JAK Inhibitors in Patients with Rheumatoid Arthritis.
Diagnostics (Basel)
; 14(8)2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38667479
5.
Management of systemic lupus erythematosus: A new scenario.
Best Pract Res Clin Rheumatol
; : 101895, 2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37978040
6.
Understanding and managing cardiac involvement in systemic sclerosis.
Expert Rev Clin Immunol
; 19(3): 293-304, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36690592
7.
EULAR 2023 Recommendations for the Management of Systemic Lupus Erythematosus: One Step Forward.
Mediterr J Rheumatol
; 35(1): 63-65, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38736951